| | [Table 19] |
|---|
| | 2nd Quarter
2009 | 2nd Quarter
2010 | 1st Half
2009 | 1st Half
2010 |
| | € million | € million | € million | € million |
| Net sales | 8,009 | 9,179 | 15,904 | 17,495 |
| Cost of goods sold | (3,794) | (4,464) | (7,580) | (8,374) |
| Gross profit | 4,215 | 4,715 | 8,324 | 9,121 |
| | | | | |
| Selling expenses | (2,033) | (2,258) | (3,993) | (4,224) |
| Research and development expenses | (663) | (747) | (1,320) | (1,464) |
| General administration expenses | (404) | (434) | (806) | (839) |
| Other operating income | 412 | 172 | 546 | 206 |
| Other operating expenses | (506) | (443) | (757) | (598) |
| Operating result [EBIT] | 1,021 | 1,005 | 1,994 | 2,202 |
| | | | | |
| Equity-method loss | (13) | (12) | (26) | (32) |
| Non-operating income | 195 | 160 | 478 | 315 |
| Non-operating expenses | (474) | (409) | (1,078) | (788) |
| Non-operating result | (292) | (261) | (626) | (505) |
| | | | | |
| Income before income taxes | 729 | 744 | 1,368 | 1,697 |
| | | | | |
| Income taxes | (199) | (220) | (414) | (479) |
| | | | | |
| Income after taxes | 530 | 524 | 954 | 1,218 |
| of which attributable to non-controlling interest | (2) | (1) | (3) | 0 |
| of which attributable to Bayer AG stockholders (net income) | 532 | 525 | 957 | 1,218 |
| | € | € | € | € |
| Earnings per share | | | | |
| Basic* | 0.67 | 0.63 | 1.22 | 1.47 |
| Diluted* | 0.67 | 0.63 | 1.22 | 1.47 |
| * The ordinary shares that resulted from conversion of the mandatory convertible bond were treated as already issued shares following the issuance of the bond. |